Recent Advances in Endometrial Cancer
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 3302
Special Issue Editor
Interests: endometrial cancer; molecular classification; surgical staging; surgery; target therapy; gynecologic oncology; precision medicine; immunohistochemistry
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Endometrial cancer (EC) is the fourth most widespread malignancy in developed countries and the first gynecologic cancer in the United States, and its incidence is expected to double in the next 10 years. In recent years, the Cancer Genome Atlas (TCGA) results have renovated the EC classification: four genomic classes with different oncological outcomes (POLE (good prognosis); high-copy-number tumors with TP53 mutations (poor prognosis); hypermutated tumors with microsatellite instability, MSI (good-to-intermediate prognosis) and low copy number (good-to-intermediate prognosis)). This innovative way to define the EC has led to a new tendency to reframe EC clinical and pathological history. After this, the TGCA molecular classification received an external and real-life-based validation based on several studies that confirmed the validity of this new EC stratification (such as PORTEC 3, etc). A fundamental step was the transition from the tumor DNA sequencing to immunohistochemistry (IHC) analysis of the molecular classification with the ProMisE study that outlined four different prognostic EC sub-groups almost superimposable to the TCGA genomic classes. These subgroups were defined as follows: POLE-mutated (good prognosis), p53-abnormal (poor prognosis), mismatch repair deficient, MMRd (good-to-intermediate prognosis) and p53-wild-type (good-to-intermediate prognosis). Of note, the p53-wild-type, also known as “no specific molecular profile” (NSMP), represents the most prevalent group of EC (39–64% within the overall EC population). So, other molecular markers were investigated to further understand the shadow areas that still persist. Recently, on these bases, the ESGO/ESTRO/ESP guidelines classification system was introduced, combining the pathological and clinical features to the new molecular information in the EC risk stratification and management. Waiting for the result of the PORTEC 4a study that will define the correct therapeutic management with adjuvant therapy and the EUGENIE trial that will indicate the proper surgical staging for each molecular class, the aim of this Special Issue is to describe the updates about the classification and management of EC in the context of this new molecular era.
Dr. Emanuele Perrone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- endometrial cancer
- molecular classification
- surgical staging and surgery
- target therapy
- gynecologic oncology
- precision medicine
- immunohistochemistry
